Skip to main content

Spectrum: Autism Research News

Author

Peter Hess

Former News Writer

Peter Hess was a reporter for Spectrum from 2019 to 2023, where he covered cannabinoids, autism prevalence, social hormones and other topics. Before joining Spectrum in 2019, he was associate science editor at Inverse, where he wrote and edited stories for a broad audience on a wide range of scientific topics, including drugs, evolution and environmental science. His work has also appeared in The Washington PostNew ScientistPopular Science and Motherboard. Peter has an M.A. in science journalism from New York University’s Science, Health and Environmental Reporting Program. Find him on Twitter at @PeterNHess.

March 2023
Illustration of a single patient in a clinical trial sitting on a bed in a glitchy, imperfectly rendered room.

Lessons from n-of-1 trials: A conversation with Joseph Gleeson

by  /  30 March 2023

Some conditions are too rare for conventional drug trials, leading some scientists to test bespoke treatments in single participants. Gleeson discusses the merits — and limitations — of these tiny trials.

Comments
A hand reaches from above to add a pill to a stack that is resting against the x-axis of a graph.

Going on Trial: Trofinetide approval for Rett; n-of-1 ASO therapies; cord-blood deals

by  /  30 March 2023

This month’s issue of the Going on Trial newsletter examines personalized therapies for rare conditions, Acadia’s new drug for Rett syndrome and developments in a cord-blood program, among other autism-related drug trial news.

Comments
Overhead picture of a racially diverse group of children playing while lying on a blue carpet.

U.S. autism prevalence continues to rise as race and sex gaps shrink, new stats show

by  /  23 March 2023

About 1 in 36 children in the United States has autism, up almost 20 percent from the previous estimate, reflecting improved identification, particularly among girls and Black, Hispanic and Asian or Pacific Islander children.

Comments
Research image of cultured neurons.

Cannabis compound rebalances signaling to quell seizures in mice

by  /  22 March 2023

Cannabidiol (CBD) blocks the action of a molecule that drives an overexcitability feedback loop in a rodent model of epilepsy.

Comments
Week of MarchMar
13th
2023

Spotted around the web: Brain imaging replicability; CRISPR-edited neurons; sex-based variability in mice

by , ,  /  17 March 2023

Here is a roundup of news and research for the week of 13 March.

Comments
Week of FebruaryFeb
27th
2023

Spotted around the web: Synaptic vesicle recycling; telehealth diagnoses; registered reports

by , ,  /  3 March 2023

Here is a roundup of news and research for the week of 27 February.

Comments
February 2023
Illustration of a sheet of red and white pills, with the red pills arranged in the form of a question mark.

Going on Trial: Orphan drugs; CBD; bumetanide

by  /  28 February 2023

This month’s newsletter takes a close look at the orphan drug program in the United States, several cannabis-based therapies and a secondary analysis of bumetanide, among other new developments in autism-related drug trials.

Comments
Week of FebruaryFeb
13th
2023

Spotted around the web: Brain organoids; early IQ changes; anti-racist policies

by , ,  /  17 February 2023

Here is a roundup of news and research for the week of 13 February.

Comments
A group of children walk up stairs

Filling autism knowledge gaps in Latin America: Q&A with Cecilia Montiel-Nava

by  /  13 February 2023

Countries across Latin America and the Caribbean struggle to collect data on autism, but Cecilia Montiel-Nava and the Latin American Autism Spectrum Network are beginning to change that.

Comments
A white mouse, brown mouse and black mouse stand inside a wooden circle against a blue background.

CHD8 mutation in 33 mouse strains yields range of traits

by  /  3 February 2023

The findings put genetic background forward to help explain autism’s heterogeneity.

Comments